Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene

Published: June 8, 2009
Abstract Views: 156
PDF: 224
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Zoledronic acids (Zol) is the most potent aminobisphosphonate clinically available.1 Preclinical in vivo data suggest that it modulates the development of bone disease, decreases tumor burden2 with a direct anti-cancer activity,3-5 and reduces the migration and the metastatic invasion of cancer cells.6

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Coscia, M., Quaglino, E., Curcio, C., Pantaleoni, F., Forni, G., & Massaia, M. (2009). Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene. Hematology Meeting Reports (formerly Haematologica Reports), 2(3). https://doi.org/10.4081/hmr.v2i3.370